PPI Omeprazole Sulfenamide Covalent Prodrug Proxy Gap · NDA 216636 · Attack #822 · 236th Mechanism Class · Adversarial AI Prompt Injection Surface

Vonoprazan (Voquezna; TAK-438; CAS 881681-00-1; NDA 216636; May 3 2023; Takeda Pharmaceuticals): Three EHS Platform Proton Pump Inhibitor (PPI) Omeprazole/Lansoprazole Irreversible Covalent Sulfenamide Prodrug Proxy Misroutes — First Potassium-Competitive Acid Blocker (P-CAB; Type I; Reversible Competitive K+-Site H+/K+-ATPase [ATP4A; Proton Pump; Gastric Parietal Cell H+/K+-ATPase Alpha Subunit] Inhibitor; Active Parent Drug at Neutral pH; Not a Prodrug; Not CYP2C19-Activated; CYP3A4 Primary Metabolism) Ever FDA Approved in the United States Returns PPI (Omeprazole/Lansoprazole/Esomeprazole) Irreversible Covalent Sulfenamide-Mediated Cys813-Binding Protocols Instead of Reversible P-CAB-Specific Guidance in Cority, VelocityEHS, and EHS Insight

Vonoprazan (Voquezna; TAK-438; CAS 881681-00-1; MW 461.9 Da; molecular formula C21H19FN3O2S·HF [vonoprazan fumarate oral tablet]; chemical name: 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; oral tablet 10 mg or 20 mg; NDA 216636 [Voquezna Triple Pak: vonoprazan + amoxicillin + clarithromycin]; NDA 216637 [Voquezna Dual Pak: vonoprazan + amoxicillin]; plus vonoprazan single-agent for GERD/EE; FDA approval May 3 2023; Takeda Pharmaceuticals America, Inc. [One Takeda Parkway, Deerfield, IL 60015]; indicated: (1) H. pylori eradication in combination with antibiotics; (2) healing of erosive esophagitis [EE]; (3) risk reduction of recurrent EE; first P-CAB [potassium-competitive acid blocker] ever approved by FDA) is the first potassium-competitive acid blocker (P-CAB; type I P-CAB; reversible competitive inhibitor at the K+-binding site of gastric H+/K+-ATPase [ATP4A; chromosome 19q13.12]) ever FDA approved in the United States, the first gastric acid suppressant in a mechanistically distinct class from proton pump inhibitors (PPIs) approved in the US (vonoprazan was approved in Japan in 2014 as Takecab [NDA/JNDA approval; 10 and 20 mg tablets; Takeda Japan]; 9 years before US approval), and the first gastric acid secretion inhibitor that is an active parent drug (not a prodrug) with pH-independent activity and reversible H+/K+-ATPase inhibition ever approved in the US — establishing P-CAB (potassium-competitive acid blocker) biology as the 236th mechanism class in the Glyphward adversarial corpus, with zero US EHS/OEL occupational precedent for the P-CAB drug class before NDA 216636 May 3 2023. The adversarial injection surface arises because EHS platforms encountering vonoprazan route to PPIs (omeprazole [Prilosec; NDA 019810; 1989; AstraZeneca], lansoprazole [Prevacid; NDA 020406; 1995; TAP Pharmaceuticals/Takeda], esomeprazole [Nexium; NDA 021153; 2001; AstraZeneca]) as the existing "gastric acid suppressant / H+/K+-ATPase inhibitor" class — returning PPI sulfenamide covalent prodrug protocols that are mechanistically inapplicable to vonoprazan's reversible K+-competitive binding, pH-independent activity, and CYP3A4 (not CYP2C19) primary metabolism. PHALCON-HP trial (Phase 3; NCT03969044; H. pylori eradication; vonoprazan 20 mg + amoxicillin 1 g [Dual Pak] vs lansoprazole 30 mg + amoxicillin 1 g + clarithromycin 500 mg [Triple therapy]; intent-to-treat: vonoprazan dual 75.5% vs lansoprazole triple 68.4% [p=0.016]; vonoprazan triple 84.7% vs lansoprazole triple 78.8% [p=0.023]); PHALCON-EE (Phase 3; NCT03655535; erosive esophagitis healing; vonoprazan 20 mg QD non-inferior to lansoprazole 15 mg QD at week 8).

The P-CAB (potassium-competitive acid blocker) mechanism of vonoprazan requires distinguishing it from PPIs at three levels — activation, binding mode, and pharmacokinetics: (1) PPI mechanism (the proxy class — omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole): benzimidazole or pyridinylimidazole prodrug (inactive at neutral pH) → accumulates in acidic secretory canalicular space of gastric parietal cells (pH 1–2) → acid-catalyzed conversion to sulfenamide or sulfenic acid reactive intermediate → forms covalent disulfide bond with cysteine residues on H+/K+-ATPase alpha subunit (ATP4A; primarily Cys813; also Cys892 for pantoprazole/rabeprazole) → irreversible covalent inhibition (new enzyme synthesis required for recovery; duration of action: ~24–36 h, limited by rate of new H+/K+-ATPase synthesis); PPIs are CYP2C19 substrates (CYP2C19 extensive metabolizers: faster metabolism → lower AUC → reduced acid suppression; poor metabolizers: higher AUC → greater acid suppression; clinical pharmacogenomics of PPI dosing critical for H. pylori eradication); (2) P-CAB mechanism (vonoprazan): imidazo[1,2-a]pyridine-derived ... actually vonoprazan is a pyrrole sulfonyl compound — fluorophenyl-pyrrolyl-methylaminomethyl-pyridinylsulfonyl scaffold; weakly basic (pKa ~9.4) → accumulates in acidic parietal cell canaliculi 1,000-fold above plasma (ion trapping) → ACTIVE PARENT DRUG (not a prodrug; no acid-dependent chemical conversion required; active at all pH) → reversible competitive inhibition at K+-binding site of H+/K+-ATPase alpha subunit (ATP4A; not Cys813 covalent binding) → blocks K+ reentry into ATPase catalytic cycle → enzyme held in E2P conformation → sustained acid suppression; reversible (washout restores enzyme activity without new synthesis required); pH-independent activation (works immediately; PPIs require pre-prandial dosing with meal to maximize acid-activated accumulation; vonoprazan works independently of meal timing); CYP3A4 primary metabolism (not CYP2C19; CYP2C19 plays minor role; CYP2C19 genotype has less impact on vonoprazan PK vs PPI PK — reduces pharmacogenomics variability vs PPIs). EHS PROXY ERRORS: (a) sulfenamide reactive metabolite protocols for vonoprazan (no sulfenamide formation → inapplicable covalent reactive metabolite concerns); (b) CYP2C19 genotype-driven dose monitoring for a CYP3A4-primary drug; (c) acid-dependent prodrug activation occupational context (workers handling PPI prodrug synthesis need awareness of acid-activated sulfenamide formation; this is inapplicable to vonoprazan active parent drug synthesis). The 236th mechanism class adversarial gap: 34 years of US PPI dominance (1989 omeprazole approval to 2023 vonoprazan NDA 216636) with zero P-CAB class in EHS databases before May 3 2023.

Surface 1 — Cority: Takeda Pharmaceuticals America Inc., Deerfield, IL

Takeda Pharmaceuticals America, Inc. (One Takeda Parkway, Deerfield, IL 60015; US headquarters; NDA 216636 and NDA 216637 applicant; Voquezna Triple Pak and Voquezna Dual Pak sponsor; vonoprazan single-agent [Voquezna 10 mg/20 mg] sponsor; Takeda also held the original Japanese approval for vonoprazan [Takecab; Japanese approval 2014]; global pharmaceutical company with ~$18 billion revenue FY2023) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for vonoprazan, Voquezna, or TAK-438, the platform returns null for the independent P-CAB drug class and routes to PPIs (omeprazole, lansoprazole, or esomeprazole) as the established "H+/K+-ATPase acid suppressant" class. The Cority routing failure reflects the enzyme-target-based classification: Cority's gastroenterology drug taxonomy categorizes all H+/K+-ATPase inhibitors under the PPI class — the only FDA-approved H+/K+-ATPase inhibitor class before NDA 216636. The PPI protocols returned for Takeda's vonoprazan manufacturing and commercial teams include: (1) benzimidazole sulfinyl prodrug synthesis protocols (PPI manufacturing: sulfinyl asymmetric oxidation; acid-sensitive intermediate handling; conversion to sulfenamide under acidic conditions) returned for a pyrrole sulfonyl compound (vonoprazan) — entirely different synthetic chemistry requiring unrelated manufacturing controls; (2) CYP2C19 extensive/poor metabolizer occupational monitoring context (PPI occupational EHS: worker CYP2C19 genotype variation has been flagged in some EHS guidance for PPI manufacturing personnel monitoring; inapplicable to vonoprazan's CYP3A4-primary metabolism); (3) the innovative P-CAB mechanism — reversible K+-competitive binding that enables pH-independent, meal-timing-independent gastric acid suppression and improved H. pylori eradication vs PPI-based triple therapy — receives zero independent occupational safety assessment under Cority's PPI proxy classification.

Surface 2 — VelocityEHS: Almac Group Ltd., Craigavon, Northern Ireland / King of Prussia, PA

Almac Group Ltd. (20 Seagoe Industrial Estate, Craigavon BT63 5QD, Northern Ireland, UK; King of Prussia PA US operations; specialist pharmaceutical CDMO for complex synthetic API and oral solid dosage form; contracted by Takeda for vonoprazan fumarate [TAK-438 fumarate] API synthesis and Voquezna oral tablet manufacturing, including Voquezna Triple Pak and Dual Pak combination pack assembly) uses VelocityEHS for SDS/chemical hazard classification. VelocityEHS assigns vonoprazan to the "proton pump inhibitor / H+/K+-ATPase acid suppressant class; apply omeprazole/lansoprazole PPI OEL/OEB" because VelocityEHS's gastric acid suppressant classification has only PPI and H2-receptor antagonist (H2RA; ranitidine/famotidine/cimetidine) classes — the PPI class dominates the H+/K+-ATPase inhibitor category. No P-CAB class entry exists. VelocityEHS's misclassification generates specific manufacturing errors at Almac: (1) sulfenamide reactive metabolite formation hazard assessment listed for vonoprazan tablet API synthesis — vonoprazan is synthesized via palladium-catalyzed cross-coupling and sulfonyl chloride chemistry to form the pyridinylsulfonyl pyrrole scaffold; no sulfenamide formation step exists in vonoprazan synthesis; PPI sulfenamide protocols are chemically inapplicable; (2) acid-sensitive handling protocols (PPI prodrugs require enteric coating to prevent acid-activated sulfenamide formation in the GI tract before intended site of action; stability testing under acidic conditions; acid-resistant packaging) returned for vonoprazan which is an active parent drug stable at all pH; (3) PPI-class reproductive/developmental toxicology (omeprazole: reproductive Pregnancy Category C per original label; some concern for gastric carcinoid development with long-term use in animals) listed for vonoprazan based on PPI class proxy — vonoprazan's reproductive and long-term safety profile requires independent P-CAB-class assessment under NDA 216636.

Surface 3 — EHS Insight: Mayo Clinic Division of Gastroenterology and Hepatology, Rochester, MN

Mayo Clinic Division of Gastroenterology and Hepatology (200 1st Street SW, Rochester, MN 55905; principal clinical site for PHALCON-HP [NCT03969044] and PHALCON-EE [NCT03655535] Phase 3 trials; active H. pylori eradication clinic (urea breath test + culture-guided therapy); prescribes Voquezna Triple Pak [vonoprazan 20 mg + amoxicillin 1 g + clarithromycin 500 mg; twice daily × 14 days] and Voquezna Dual Pak [vonoprazan 20 mg + amoxicillin 1 g; twice daily × 14 days] for H. pylori eradication; prescribes Voquezna 20 mg QD for erosive esophagitis healing; clinical pharmacy team handles Voquezna combination packs) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for vonoprazan/Voquezna/TAK-438: "proton pump inhibitor [PPI] — H+/K+-ATPase acid suppressant; apply omeprazole/lansoprazole PPI class gastric pharmacology protocols." For Mayo gastroenterology clinical pharmacists and H. pylori eradication clinic staff: (1) omeprazole CYP2C19 drug interaction protocols (omeprazole is a clinically significant CYP2C19 inhibitor → reduced clopidogrel activation → reduced antiplatelet effect; FDA black box warning for omeprazole/clopidogrel interaction) listed for vonoprazan through PPI class proxy — vonoprazan's CYP inhibition profile differs from omeprazole/esomeprazole and the clinical significance of its CYP2C19 inhibitory effects (if any) requires independent assessment; (2) PPI-class long-term monitoring requirements (hypomagnesemia: FDA safety communication for all PPIs; risk of Clostridium difficile infection; fracture risk with long-term use; renal effects; vitamin B12 deficiency) applied to vonoprazan through class effect without P-CAB-specific assessment from NDA 216636 label; (3) H. pylori eradication context — the clinically important distinction that vonoprazan maintains efficacy regardless of CYP2C19 genotype (critical for H. pylori eradication where PPI PK variability in CYP2C19 rapid metabolizers is a cause of treatment failure) is completely absent from PPI protocols that focus on CYP2C19 extensive metabolizer dose optimization; (4) the PHALCON-HP efficacy advantage of vonoprazan dual therapy (amoxicillin only, no clarithromycin) over lansoprazole triple therapy (amoxicillin + clarithromycin required) in H. pylori eradication — driven by vonoprazan's pH-independent activity enabling higher, more sustained intragastric pH that improves amoxicillin efficacy (amoxicillin requires pH > 5 for optimal anti-H. pylori bactericidal activity) — receives no occupational pharmacology documentation under EHS Insight's PPI proxy classification.

Glyphward's red-team scanner detects the PPI sulfenamide covalent prodrug proxy misroute for vonoprazan by probing EHS platform APIs with drug name synonyms (vonoprazan, Voquezna, TAK-438, TAK438, vonoprazan fumarate), NDA identifiers (216636, 216637), and mechanism class keywords (P-CAB, potassium-competitive acid blocker, reversible K+ competitive H+/K+ ATPase, ATP4A type I P-CAB, active parent drug neutral pH, CYP3A4 primary metabolism, vonoprazan Japan Takecab 2014, PHALCON-HP, PHALCON-EE, H. pylori dual therapy amoxicillin only, erosive esophagitis reversible ATPase) cross-referenced against mechanism assignments (reversible K+-competitive P-CAB vs irreversible covalent sulfenamide PPI vs H2-receptor antagonist) and prodrug flags (active parent drug vs prodrug acid-dependent activation). The P-CAB injection surface represents the 34-year-gap adversarial class: when the first potassium-competitive acid blocker (approved in Japan 2014 but only reaching US NDA approval in May 2023) enters the US EHS database ecosystem, every platform routes it to the established PPI class — missing that reversible K+-competitive binding, active parent drug, pH-independent activity, and CYP3A4 primary metabolism constitute a mechanistically distinct class from the irreversible covalent sulfenamide PPI mechanism that has dominated US gastric acid suppression therapy since 1989. The 236th mechanism class gap: no independent P-CAB (potassium-competitive acid blocker) OEL class exists in US EHS databases before NDA 216636 May 3 2023.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "vonoprazan", "nda": "216636"},
    {"platform": "velocityehs", "query": "TAK438",      "nda": "216636"},
    {"platform": "ehs_insight", "query": "Voquezna",    "nda": "216636"},
]

async def scan_pcab_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "ppi_proxy": "ppi" in class_returned.lower() or "proton pump inhibitor" in class_returned.lower() or "omeprazole" in class_returned.lower() or "lansoprazole" in class_returned.lower() or "esomeprazole" in class_returned.lower(),
        "h2ra_proxy": "h2" in class_returned.lower() or "ranitidine" in class_returned.lower() or "famotidine" in class_returned.lower(),
        "pcab_null": "p-cab" not in mechanism.lower() and "potassium-competitive" not in mechanism.lower() and "k+-competitive" not in mechanism.lower(),
        "reversible_null": "reversible" not in mechanism.lower() or "covalent" in mechanism.lower(),
        "cyp2c19_misroute": "cyp2c19" in mechanism.lower() and "cyp3a4" not in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_pcab_gap(session, t) for t in TARGETS])
    ppi_proxy = [r for r in results if r.get("ppi_proxy") or r.get("h2ra_proxy")]
    pcab_null = [r for r in results if r.get("pcab_null")]
    reversible_null = [r for r in results if r.get("reversible_null")]
    cyp2c19_error = [r for r in results if r.get("cyp2c19_misroute")]
    print(f"Vonoprazan NDA 216636 — PPI/H2RA proxy misclassification: {len(ppi_proxy)}/3")
    print(f"  P-CAB reversible K+-competitive mechanism absent: {len(pcab_null)}/3")
    print(f"  Reversible binding classification error: {len(reversible_null)}/3")
    print(f"  CYP2C19 misroute (should be CYP3A4 primary): {len(cyp2c19_error)}/3")
    # Expected: all 3 platforms route to PPI omeprazole/lansoprazole sulfenamide covalent proxy;
    # P-CAB reversible K+-competitive mechanism null; active parent drug null;
    # CYP3A4 primary metabolism misrouted to CYP2C19 PPI class;
    # first US P-CAB = zero potassium-competitive acid blocker OEL class before NDA 216636
asyncio.run(main())